Dipartimento di Medicina Clinica e Sperimentale, Università di Verona, Verona, Italy.
Clin Rheumatol. 2010 Dec;29(12):1419-25. doi: 10.1007/s10067-010-1478-3. Epub 2010 May 9.
Vitamin D displays many extraosseous immunomodulatory effects. The aim of the study was to evaluate the level of vitamin D in patients with systemic sclerosis (SSc) and to analyze the associations between the concentration of the vitamin and clinical manifestations. In March-April 2009, 65 consecutive SSc patients underwent evaluation of vitamin D concentrations by the LIAISON immunoassay (normal 30-100 ng/ml). Serum levels between 10 and 30 ng/ml were classified as vitamin D insufficiency, while concentrations <10 ng/ml as vitamin D deficiency. None of the patients were receiving vitamin D supplementation at the time of or during the year prior to study entry. The mean level of vitamin D was 15.8 ± 9.1 ng/ml. Only three cases showed normal values; vitamin D insufficiency and deficiency were found in 43 and 19 cases, respectively. Patients with vitamin D deficiency showed longer disease duration (13.1 ± 6.8 versus 9.4 ± 5.5 years, P = 0.026), lower diffusing lung capacity for carbon monoxide (63.7 ± 12.4 versus 76.4 ± 20.2, P = 0.014), higher estimated pulmonary artery pressure (28.9 ± 9.9 versus 22.8 ± 10.4, P = 0.037) and higher values of ESR (40 ± 25 versus 23 ± 13 mm/h, P = 0.001) and of CRP (7 ± 7 and 4 ± 2 mg/l, P = 0.004) in comparison with patients with vitamin D insufficiency; moreover, late nailfold videocapillaroscopic pattern was more frequently found (52.6% versus 18.6%, P = 0.013). None of the patients showed evidence of overt mal-absorption. Low levels of vitamin D are very frequent in patients with SSc. Intestinal involvement is not likely the cause of vitamin D deficit; other factors such as skin hyperpigmentation and reduced sun exposition for psychological and social reasons may be implicated. Patients with vitamin D deficiency showed more severe disease in comparison with patients with vitamin D insufficiency, above all concerning lung involvement. Further trials are awaited to determine whether vitamin D could represent a modifiable factor able to interfere with SSc evolution.
维生素 D 具有许多骨外免疫调节作用。本研究的目的是评估系统性硬化症(SSc)患者的维生素 D 水平,并分析维生素浓度与临床表现之间的关系。2009 年 3 月至 4 月,连续 65 例 SSc 患者采用 LIAISON 免疫分析法测定维生素 D 浓度(正常值 30-100ng/ml)。血清浓度在 10-30ng/ml 之间被归类为维生素 D 不足,而浓度<10ng/ml 则被归类为维生素 D 缺乏。在研究入组时或入组前 1 年内,没有患者接受维生素 D 补充治疗。维生素 D 的平均水平为 15.8±9.1ng/ml。只有 3 例患者的检测值正常,43 例患者存在维生素 D 不足,19 例患者存在维生素 D 缺乏。维生素 D 缺乏的患者疾病持续时间更长(13.1±6.8 年比 9.4±5.5 年,P=0.026),一氧化碳弥散量更低(63.7±12.4 比 76.4±20.2,P=0.014),估计肺动脉压更高(28.9±9.9 比 22.8±10.4,P=0.037),血沉(40±25 比 23±13mm/h,P=0.001)和 C 反应蛋白(7±7 和 4±2mg/L,P=0.004)值更高,且晚期甲襞毛细血管镜下模式更为常见(52.6%比 18.6%,P=0.013)。没有患者表现出明显的吸收不良。SSc 患者维生素 D 水平普遍较低。肠道受累不太可能是维生素 D 缺乏的原因;其他因素,如皮肤色素沉着和因心理和社会原因减少阳光暴露,可能与之相关。与维生素 D 不足的患者相比,维生素 D 缺乏的患者疾病更为严重,尤其是肺部受累。需要进一步的试验来确定维生素 D 是否可以作为一个可改变的因素来干预 SSc 的进展。